Inhalon launches human challenge trial for RSV treatment
US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...
Flu cases continue to rise, RSV and COVID rates decrease nationally: The latest on respiratory virus season for week of Feb. 3
Cases of influenza continue to soar across Canada, meanwhile rates of respiratory syncytial virus, or RSV, and COVID-19 are ...
Managed Healthcare Executive13d
A Look at Human Metapneumovirus — a Respiratory Virus You've Likely Had Without Knowing
Human Metapneumovirus (HMPV) is a respiratory virus that may not be on most folk’s radars, but it’s more common than you ...
GlobalData on MSN5d
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial
Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.
Virus infection rate rises in UK update as young 'most vulnerable' and NHS advises masks
Hospitals in China have been 'overwhelmed' by outbreak says WHO as NHS says people with respiratory symptoms should 'limit ...
Virus spreading in China raises concerns in the United States
A virus rapidly spreading in China is also circulating in the United States, causing concern among health experts.
Hosted on MSN5d
Are HMPV and RSV the same? Know more about these respiratory viruses
In the wake of multiple cases of human metapneumovirus (hMPV) in India, multiple questions about its causes and symptoms seem ...
hVIVO wins contract for RSV drug human trial for Inhalon Biopharma
(Alliance News) - hVIVO PLC on Monday said it has signed a contract with Inhalon Biopharma Inc to test its antiviral candidate to treat respiratory syncytial virus. The London-based contract research ...